Curriculum Vitae

Scott M. Lieberman, MD, FACC
1783 Troup Hwy, Tyler, Texas 75701
Office (903)-595-2283 Fax (903)-597-2238

Practice

2009-Present	Tyler Cardiac and Endovascular Center -1769 Troup Hwy, Tyler, Texas
1994-Present	Cardiovascular Associates of East Texas, P.A., Tyler, Texas

Affiliation

1994-Present	CAET - Research - 1761 Troup Hwy, Tyler, Texas
1/1/13-4/26/13	TAD Clinical Research - 1741 Troup Hwy, Tyler, Texas

Education

Post-doctoral Training

Fellowship

7/1993-6/1994	Interventional Cardiology Fellow, Section of Cardiology Lenox Hill Hospital, New York City
7/1990-6/1993	Cardiovascular Diseases Fellow Lenox Hill Hospital, New York City

Elective

10/1989-11/1989	Texas Heart Institute, Cardiovascular Service St. Luke's Hospital, Houston Texas

Residency

1987-1990	Categorical Internal Medicine (3 Year Program), Lenox Hill Hospital, New York City

Medical School

1983-1987	New York Medical College Valhalla, New York

College

5/22/1983	Bachelor of Science Degree, Double Major in Chemistry and Biology
1979-1983	Wagner College Staten Island, New York

Licensure

Texas State License

New York State License

Advanced Cardiac Life Support (ACLS)

Basic Life Support (BLS)

Hospital Appointments

CHRISTUS Trinity Mother Frances, Tyler, Texas

CHRISTUS Trinity Mother Frances, Jacksonville, Texas

UT Health East Texas (ETMC), Tyler, Texas

UT Health East Texas (ETMC), Carthage, Texas

UT Health East Texas (ETMC), Quitman, Texas

Baylor Scott & White Texas Spine and Joint, Tyler, Texas

The University of Texas Health Science Center at Tyler, Tyler, Texas

Research

Co-Investigator - FORXIGA-HF - Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction. (D1699C00001)

Co-Investigator - PROVE-HF - A 52 Week, open label evaluation on the effects of sacubitril/valsartan (LCZ696) therapy on biomarkers, myocardial remodeling and patient-reported outcomes in heart failure with reduced left ventricular ejection fraction.

Co-Investigator - RANGER II SFA - A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)

Co-Investigator - REVEAL - Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization. (The REVEAL Study)

Co-Investigator - TOBA II BTK - Tack Optimized Balloon Angioplasty Study for the Below The Knee Arteries Using the Tack Endovascular System® (TOBA II BTK)

Co-Investigator – COPPER A – "The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis – Above the Knee"

Co-Investigator - VOYAGER-PAD – An international, multicenter randomized, double-blind, placebo controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.

Co-Investigator - CHAMP-HF – Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction.

Co-Investigator – ABLATE - The trial is a prospective, multi-center, non-randomized registry evaluating the safety and effectiveness of Excimer Laser Atherectomy (ELA) using the Spectranetics Turbo-Elite Laser Ablation Catheter.

Co-Investigator – AVERT - **"**A prospective, randomized, parallel group, multi-center clinical evaluation, to

assess the AVERT system device for CM volume reduction and incidence of CIN".

Co-Investigator – CAMELLIA - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.

Co-Investigator – LIBERTY 360 - Prospective, observational, multi-center clinical study to evaluate endovascular device interventions in treating lower extremity PAD with critical limb ischemia (CLI) and/or intermittent claudication.

Co-Investigator – MIMICS-2 - Evaluation of Safety and Efficacy of the BioMimics 3DTM Stent System in the Femoropopliteal Arteries of Patients with Symptomatic Peripheral Arterial Disease.

Primary Investigator - DECLARE – A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Co-Investigator - ODYSSEY – A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.

Co-Investigator - SUMMIT – HZC113782 A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease

Co-Investigator - ABSORB III - Randomized Controlled Trial. A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of Subjects with de novo Native coronary Artery Lesions.

Co-Investigator – AD HOC PCI – A randomized, open-label, multiple-center, parallel group, study to compare the platelet inhibition with Verify Now™ assay of ticagrelor vs. clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)

Co-Investigator – EXCITE – Excimer laser randomized Controlled study for treatment of femoropopliteal In-Stent Restenosis.

Co-Investigator – EUCLID –A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD)

Co-Investigator – PARADIGM - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.

Primary Investigator - TRA2P - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50).

Co-Investigator – LIBERTE – "A prospective, multi-center study designed to observe clinical outcomes in

patient receiving the TAXUS Liberte-Paclitaxel-Eluting Coronary Stent and prasugrel as part of a dual antiplatelet therapy drug regimen.
Co-Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.

Primary Investigator - APEX-AMI Study - "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention." (Assessment of PEXelizumab in Acute Myocardial Infarction)-APEX-AMI.

Co-Investigator – RE-LY - **R**andomized **E**valuation of **L**ong term anticoagulant therap**y** (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.

Co-Investigator – ENDEAVOR IV – A Randomized, Controlled Trial of the Medtronic Endeavor Drug Eluting Coronary Stent System versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Co-Investigator – A-HeFT - A Placebo-Controlled Trial of Bidil Added to Standard Therapy In African-American Patients with Heart Failure.

Co-Investigator - ACCOMPLISH- A prospective, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine/benazepril to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension.

Primary Investigator - AMIHOT II – A prospective, Multi-center, randomized study of Aqueous Oxygen Therapy for 90 minutes in Anterior Acute MI patients with successful PCI/stenting presenting within 6 hours from time of symptom onset until time of reperfusion.

Primary Investigator – TIMI38/TRITON – A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Patients who are to Undergo Percutaneous Coronary Intervention; a Phase III, multicenter, randomized, parallel-group, double-dummy, active controlled trial in patients with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI).

Co-Investigator – VISION 305 Study - "Vasodilator Induced Stress In Concordance with Adenosine" A multicenter, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-controlled, complete two-arm crossover study with a reference third arm.

New York Medical College Summer Research Grant Recipient

Tanney Fellow in Sports Medicine and Cardiovascular Research

Co-investigator-Coumadin, Aspirin and Reinfarction Study; "CARS" DuP 647-003 A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients

Co-investigator-Coumadin, Aspirin and Reinfarction EKG Substudy; "CARS" DuP 647-003 A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.

Co-Investigator-PACT trial (Plasminogen-Activator Angioplasty Compatibility Trial) A randomized, double-blind placebo controlled study assessing clinical efficacy of bolus infusion of TPA to placebo in acute MI

patients with rescue angioplasty.

Co-investigator-PRAISE 2 - (Prospective Randomized Amlodipine Survival Evaluation - 2) Phase III Protocol NO. 053-185: A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of Amlodipine on survival in patients with congestive heart failure.

Co-investigator-MK-383 Protocol #008-00; A randomized, double-blind study of MK-383 in patients with unstable angina pectoris concomitantly receiving Heparin.

Co-investigator-IMDUR (isosorbide mononitrate) P94-070 Phase IV Patient Acceptability Program. A study comparing the efficacy, safety and ease of use of three FDA-approved formulations; IMDUR, ISDN, and ISMO. The study design assesses if patients with stable angina pectoris benefit - in terms of fewer anginal attacks, increased exercise tolerance, simplicity and convenience of use. IMDUR (isosorbide mononitrate).
Co-investigator-BioSlide Catheter - SCIMED

Co-investigator & Site Coordinator - (GUSTO)-University of Michigan: Global Utilization of Streptokinase and tissue plasminogen activator for occluded coronary arteries.

Co-Investigator - GUSTO IV AMI (Protocol CO116T31): A Phase III, randomized, open-label trial evaluating the efficacy and safety of ReoPro™ (ABCIXIMAB) in combination with reduced dose Retavase™/Rapilysin™ (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.

Catecholamine Levels During Exercise Testing for Arrhythmia; Relation to Venous Lactate levels.

Intra-Coronary Echocardiography (I.V.U.S.) of Native Coronaries, Bypass Grafts, and comparison to Digital Quantitative Angiography (Q.C.A.).

Intra-Coronary Ultrasound (I.V.U.S.) Comparison to Intra-Coronary Angioscopy in Coronary Interventions. A Qualitative Assessment.

Principal Investigator - Paragon B Trial Phase III (BC 156 86; RO 44-9883): A randomized, double-blind placebo-controlled study of Lamifiban in patients with unstable angina/non-Q wave myocardial infarction.

Co-Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarction.

Sub- Investigator – EPHESUS – IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction.

Co-Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.

Co-Investigator – VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.

Principal Investigator – MICCAT (MICardis Community Access Trial) An Phase IV – Open label evaluation of the effectivness of Micardis® (telmisartan) on blood pressure control and quality of life in patients with essential hypertension.

Co-Investigator - Niaspan Trial #MA-97-0101 Phase IV: an open-label, community-based clinical practice study of Niaspan in patients with hyperlipidemia.

Co-Principal Investigator - CardioGenesis Transmyocardial Revascularization (TMR) System: To evaluate the safety and efficacy of the CardioGenesis TMR System when used for TMR performed as an adjunct to CABG in patients with angina resulting from coronary artery disease which is only partially treatable by CABG.

Co-Investigator - ATLAS Trial (Aspirin TicLid vs Anticoagulation for Stents) - George Washington University, Cardiovascular Research Institute.

Principal Investigator - DESTINI (Doppler Endpoint Stenting International Investigation): A multicenter randomized prospective evaluation of clinical outcome comparing primary stenting and a new practice pattern of optimal balloon angioplasty guided by quantitative angiography and intracoronary Doppler.

Co-Investigator - NRMI - National Registry for Myocardial Infarction.

Co-Principal Investigator - TMR012-A. A single-blind, randomized study of the safety and effectiveness of percutaneous transluminal myocardial revascularization (PTMR) performed with the Eclipse Holmium Laser as an adjunct to percutaneous coronary intervention.

Investigator – ER-TIMI 19 – A Phase IV, Open-Label Trial of Prehospital Administration of Retavase® for ST elevation MI – the Early Retavase® (ER) – TIMI 19 Trial.
Co-Investigator – Left Main IVUS Registry – Scripps Clinic – A multicenter prospective registry designed to determine the value of diagnostic IVUS in the setting of an inconclusive coronary angiogram.

Co-Investigator – GUSTO IV ACS – A phase III, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ReoPro™, given as a bolus followed by a 24- or 48-hour infusion, for the treatment of acute coronary syndrome without ST-segment elevation.

Principal Investigator – STEP AMI – An Open Study, with Blinded Endpoint Assessment, to Assess the Safety, Tolerability and the Effect on Coronary Artery Patency of Intravenous AR-C69931MX as both Monotherapy and Adjunct to Activase in Patients with ST-elevation Myocardial Infarction.
Co-Investigator – REPLACE – TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.

Co – Investigator - OCTAVE - CV137-120 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) A Phase III, Randomized, Double Blind, Active Controlled Comparison of Omapatrilat and Enalapril in Subjects with newly Diagnosed or Established Hypertension

Co-Investigator – CRISP - A single Arm, Open label Study of Cervastatin (Baycol®) in Community based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease to Monitor inflammatory markers

Principal Investigator – SYNERGY - A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (ACS). Aventix Pharmaceuticals Protocol Number ENO.GMA.301. IND# 31532

Co-Investigator – A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of

Intravenous Amiodarone: Cordarone® I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US

Co-Investigator-INSPIRE :A Randomized, Prospective Multicenter Trial Evaluating The Role Of Adenosine Tc99m Sestamibi SinglepPhoton Emission Computed Tomography For Assessing Risk And Therapeutic Outcomes In Survivors Of Acute Myocardial Infarction.

Co-Investigator – Otsuka Protocol 21-98-214-01 CASTLE " A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Asses The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease".

Principal Investigator – AMIHOT – TherOx Aqueous Oxygen System – Acute Myocardial Infarction with Hyperoxemic Therapy "AMIHOT" Phase II clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.

Principal Investigator – A Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina

Co-Investigator – Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System

Co-Investigator- – ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome without ST-segment elevation.

Co-Investigator – ENDEAVOR SVS Registry: "A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single *De novo* Lesions in Small Diameter Native Coronary Arteries"

Co-Investigator – Taxus Libertē "A prospective, multi-center study designed to observe clinical outcomes in patient receiving the TAXUS Libertē-Paclitaxel-Eluting Coronary Stent and prasugrel as part of a dual antiplatelet therapy drug regimen"

Co-Investigator – TAO: "A randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy"

Principal Investigator – TRACER "A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome"
Principal Investigator – IMPROVE IT - A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial

Principal Investigator - Vista 16 - Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes